ANVS
Annovis Bio, Inc.
NYSE · Healthcare · Biotechnology · US
$1.39
+0.72%Next report
Analyst consensus
- Next report date
- Nov 11, 2026
- EPS estimate
- -$0.30
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 14, 2026
- EPS actual
- -$0.40
- EPS estimate
- -$0.45
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 7
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -19.2%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $12
- PT range
- $7.00 – $17
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 11, 2026